PDF下载 ( 1755 KB)
Value of HBsAg level in dynamic monitoring of disease progression in patients with chronic HBV infection
-
摘要: 目的探讨HBsAg水平在慢性HBV感染者疾病进展监测中的临床价值。方法收集2011年5月-2015年12月在安徽医科大学第二附属医院门诊及住院时未进行抗病毒治疗的1107例不同临床阶段的慢性HBV感染者的临床资料,并根据疾病状态分为HBeAg阳性慢性乙型肝炎组（HBeAg阳性CHB组,n=356）、HBeAg阴性慢性乙型肝炎组（HBeAg阴性CHB组,n=264）、乙型肝炎肝硬化代偿期组（LC-C组,n=116）、乙型肝炎肝硬化失代偿期组（LC-D组,n=201）、原发性肝癌组（PLC组,n=170）,比较不同临床阶段患者之间HBsAg表达水平的差异及HBsAg水平与临床特征的相关性。计量资料多组间比较采用方差分析,进一步两两比较采用LSD-t检验;两组间比较采用t检验。计数资料组间比较采用χ2检验。相关性分析采用Pearson检验。结果HBeAg阳性CHB组、HBeAg阴性CHB组、LC-C组、LC-D组、PLC组之间患者血清HBsAg、HBV DNA水平比较,差异均有统计学意义（F值分别为100.45、86.26,P值均<0.001）。502例HBeAg阳性患者的HBsAg、...Abstract: Objective To investigate the clinical value of HBsAg level in dynamic monitoring of disease progression in patients with chronic HBV infection. Methods A retrospective analysis was performed for the clinical data of 1107 patients with different clinical stages of chronic HBV infection who had not received antiviral therapy at the time of hospitalization in The Second Affiliated Hospital of Anhui Medical University from May 2011 to December 2015, and according to the disease status, they were divided into HBeAg-positive chronic hepatitis B ( CHB) group ( n = 356) , HBeAg-negative CHB group ( n = 264) , compensated liver cirrhosis group ( LC-C group, n = 116) , decompensated liver cirrhosis group ( LC-D group, n = 201) , and primary liver cancer ( PLC) group ( n = 170) . These groups were compared in terms of HBsAg expression and the association between HBsAg and clinical features. An analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between any two groups; the t-test was used for comparison of continuous data between two groups. The chi-square test was used for comparison of categorical data between these groups. Pearson correlation analysis was also performed. Results There were significant differences in serum HBsAg and HBV DNA level between the HBeAg-positive CHB group, HBeAg-negative CHB group, LC-C group, LC-D group, and PLC group ( F =100. 45 and 86. 26, both P < 0. 001) . The HBeAg-positive CHB group ( n = 502) had significantly higher levels of HBsAg and HBV DNA than the HBeAg-negative CHB group ( n = 605) ( t = 16. 67 and 16. 22, both P < 0. 001) . There were significant differences in HBsAg and HBV DNA levels between the HBeAg-positive CHB group, LC-C group, LC-D group, and PLC group ( F = 42. 92 and 27. 38, both P <0. 001) , as well as between the HBeAg-negative CHB group, LC-C group, LC-D group, and PLC group ( F = 6. 04 and 4. 10, both P <0. 05) . HBV DNA level was significantly different across patients with different HBsAg levels ( < 1000 IU/ml, 1000-20 000 IU/ml, and> 20 000 IU/ml) ( F = 189. 51, P < 0. 001) . In the HBeAg-positive CHB group, HBeAg-negative CHB group, LC-C group, and LC-D group, serum HBsAg level was positively correlated with HBV DNA level ( r = 0. 554, 0. 501, 0. 320, and 0. 432, all P < 0. 001) .Conclusion HBsAg level gradually decreases with disease progression and is closely associated with HBV DNA level. Dynamic monitoring of HBsAg level helps to evaluate disease progression after HBV infection.
-
Key words:
- hepatitis B virus /
- hepatitis B surface antigens /
- viral load
-
[1]TSENG TC, KAO JH.Clinical utility of quantitative HBs Ag in natural history and nucleos (t) ide analogue treatment of chronic hepatitis B:new trick of old dog[J].J Gastroenterol, 2013, 48 (1) :13-21. [2]YANG S, XING H, WANG Y, et al.HBs Ag and HBe Ag in the prediction of a clinical response to peginterferonα-2b therapy in Chinese HBe Ag-positive patients[J].Virol J, 2016, 13 (1) :180. [3]CHUAYPEN N, SRIPRAPUN M, PRAIANANTATHAVORN K, et al.Kinetics of serum HBs Ag and intrahepatic ccc DNA during pegylated interferon therapy in patients with HBe Ag-positive and HBe Ag-negative chronic hepatitis B[J].J Med Virol, 2017, 89 (1) :130-138. [4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ. [5]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159. [6] PEI YZ, HAN T, MA XY, et al.The discrepancy of HBs Ag titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma[J].Chin J Hepatol, 2011, 19 (10) :743-746. (in Chinese) 裴彦祯, 韩涛, 马晓艳, 等.HBs Ag及HBV DNA定量水平在慢性乙型肝炎、肝硬化和肝癌患者中的变化[J].中华肝脏病杂志, 2011, 19 (10) :743-746. [7]KARRA VK, CHOWDHURY SJ, RUTTALA R, et al.Clinical significance of quantitative HBs Ag titres and its correlation with HBV DNA levels in the natural history of hepatitis B virus infection[J].J Clin Exp Hepatol, 2016, 6 (3) :209-215. [8]CHAN HL, WONG VW, WONG GL, et al.A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B[J].Hepatology, 2010, 52 (4) :1232-1241. [9]GUPTA E, KUMAR A, CHOUDHARY A, et al.Serum hepatitis B surface antigen levels correlate with high serum HBV DNA levels in patients with chronic hepatitis B:a cross-sectional study[J].Indian J Med Microbiol, 2012, 30 (2) :150-154. [10] GAO YF, ZOU GZ, YE J, et al.Relationship between hepatitis B surface antigen, HBV DNA quantity and liver fibrosis severity[J].Chin J Hepatol, 2015, 23 (4) :254-257. (in Chinese) 郜玉峰, 邹桂舟, 叶珺, 等.HBs Ag和HBV DNA定量水平与肝纤维化程度的关系[J].中华肝脏病杂志, 2015, 23 (4) :254-257. [11]CHEN XF, CHEN XP, MA XJ, et al.Relationship between serum HBs Ag level and liver histological features in chronic HBV infection patients with low ALT levels[J].J Clin Hepatol, 2015, 31 (10) :1688-1691. (in Chinese) 陈学福, 陈小苹, 马晓军, 等.低ALT水平的慢性HBV感染者血清HBs Ag水平与肝组织学的相关性[J].临床肝胆病杂志, 2015, 31 (10) :1688-1691. [12]WANG XL, ZOU GZ, YE J, et al.Quantitation value of HBs Ag in different clinical stages of chronic hepatitis B virus infection[J].J Pract Med, 2014, 30 (17) :2765-2767. (in Chinese) 王晓琳, 邹桂舟, 叶珺, 等.乙肝表面抗原在慢性乙型肝炎病毒感染临床不同阶段的变化[J].实用医学杂志, 2014, 30 (17) :2765-2767. [13]CHEN W, WU F, DOU XG, et al.Analysis of related factors for intrahepatic HBV ccc DNA level in patients with chronic HBV infection[J].J Clin Hepatol, 2013, 29 (6) :434-437. (in Chinese) 陈嵬, 吴峰, 窦晓光, 等.慢性HBV感染者肝脏HBV ccc DNA含量相关因素分析[J].临床肝胆病杂志, 2013, 29 (6) :434-437. [14] HAN XY, CHEN XJ, YAN ZQ, et al.Correlation among HBs Ag and HBV DNA levels with liver fibrosis in patients with hepatitis B[J].Int J Virol, 2016, 23 (1) :50-52, 56. (in Chinese) 韩晓颖, 陈秀记, 闫泽强, 等.血清HBs Ag与HBV DNA水平与乙肝患者肝纤维化程度的相关性分析[J].国际病毒学杂志, 2016, 23 (1) :50-52, 56. 期刊类型引用(13)
1. 张沙沙，赵迎春，周红霞. 恩替卡韦经治乙肝肝硬化患者低病毒血症对肝癌发病的影响. 临床荟萃. 2024(11): 980-983 . 
百度学术2. 程齐齐，杨丽霞，蔡天盼，王亮，孙俊，梁佳圆，刘丽萍，甘厦，阮宁杭，葛善飞. 核苷（酸）类似物初治的慢性乙型肝炎患者发生低病毒血症的影响因素及其动态变化分析. 临床肝胆病杂志. 2022(12): 2716-2722 . 
本站查看3. 文静. HBV感染患者血清25(OH)D_3含量与HBV DNA载量的相关性. 医学信息. 2022(21): 81-83+91 . 百度学术4. 张瑜，路青华，曹海芳，张生荣. 聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响. 医学信息. 2021(17): 114-116 . 百度学术5. 汤雄，黄洁. HBsAg定量检测对恩替卡韦治疗HBeAg阴性慢性乙型肝炎患者停药后复发的预测效能. 中国当代医药. 2020(04): 36-39 . 百度学术6. 李莎，彭华彬，李淑芹，周静，汪莉萍. 徐州地区HBV感染者逆转录聚合酶区基因耐药变异特点及耐药影响因素分析. 临床肝胆病杂志. 2020(06): 1245-1251 . 本站查看7. 冯光安. 血清CK18 M65联合HBsAg检测对HBV携带者疾病进展的评估价值. 江苏预防医学. 2020(05): 572-573+575 . 百度学术8. 杜波，高小丽，白雪梅. 慢性乙型肝炎患者HBV-DNA载量与血清microRNA-122、ALT的相关性研究. 中国现代医学杂志. 2020(24): 86-90 . 百度学术9. 郭强，赵科孝. HBeAg阴性慢性乙肝合并肝硬化患者血清HBV-DNA水平与肝功能的相关性. 海南医学. 2019(08): 973-976 . 百度学术10. 夏红，杨强. HBV聚合酶活性区变异与临床病情变化及HBsAg阳性相关性. 中南医学科学杂志. 2019(03): 291-293+317 . 百度学术11. 白娜. 慢性乙型肝炎与肝硬化患者血清乙型肝炎表面抗原及乙型肝炎病毒DNA载量水平比较. 实用医技杂志. 2019(10): 1269-1270 . 百度学术12. 梅朝蓉，雷娜，徐静，陈琪，彭泽选，雷黎黎，刘坤，刘超，周燚，梅治家. 231例西藏地区藏族原发性肝癌的临床特征分析. 齐齐哈尔医学院学报. 2018(04): 384-387 . 百度学术13. 胡金燕，林坤培，周兰. 血清HBsAg、HBV DNA水平及相关性在慢性HBV感染过程的变化和意义. 中国医学创新. 2018(15): 8-11 . 百度学术其他类型引用(1)
-
百度学术
下载:
